DURHAM, N.C., May 27, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company has been selected as a Red Herring Top 100 North America winner. Each year Red Herring, a technology and business magazine and online news source, honors 100 outstanding entrepreneurs and promising companies as award winners from among approximately 3,000 companies financed annually in the US and Canada.
"This year has so far been momentous for Argos Therapeutics, including completion of our initial public offering, continued progress in our ADAPT pivotal Phase 3 clinical trial, presentation of long-term survival data from our Phase 2 trial for AGS-003 in the treatment of metastatic renal cell carcinoma, and continued progress on our clinical program for AGS-004 in the treatment of HIV. We are proud to have our many positive developments this year recognized through our selection as a Red Herring Top 100 winner," said Jeff Abbey, president and CEO at Argos.
Argos will be presenting the results of its completed Phase 2 combination study and ongoing pivotal ADAPT trial involving AGS-003—the company's investigational fully personalized immunotherapy for cancer—plus standard targeted therapy in poster sessions during the American Society of Clinical Oncology (ASCO) annual meeting, taking place May 30 – June 2 in Chicago.
In the award selection process, Red Herring's editorial staff evaluates companies on both quantitative and qualitative criteria such as financial performance, technological innovation, intellectual property, management quality, business model, customer footprint, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their sector peers.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.